Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224255 | 0.98 | LMNA (0.51) | LMNAHPGDHTTKMT2ASMN1; SMN2 | |
| SCHEMBL981768 | 0.91 | RIPK1 (0.53) | LMNAHPGDHTTKMT2ASMN1; SMN2 | |
| SCHEMBL18615875 | 0.84 | LMNA (0.51) | LMNAHPGDHTTKMT2ASMN1; SMN2 | |
| SCHEMBL21949703 | 0.84 | LMNA (0.51) | LMNAHPGDHTTKMT2ASMN1; SMN2 | |
| SCHEMBL18586429 | 0.84 | LMNA (0.51) | LMNAHPGDHTTKMT2ASMN1; SMN2 | |
| SCHEMBL29642919 | 0.84 | LMNA (0.51) | LMNAHPGDHTTKMT2ASMN1; SMN2 | |
| SCHEMBL20448925 | 0.84 | LMNA (0.51) | LMNAHPGDHTTKMT2ASMN1; SMN2 | |
| SCHEMBL18706829 | 0.83 | MCHR1 (0.48) | HPGDMCHR1HTR2CCNR1CNR2 | |
| SCHEMBL14858080 | 0.83 | MCHR1 (0.48) | HPGDMCHR1RIPK1THRATHRB | |
| SCHEMBL15924140 | 0.83 | RIPK1 (0.43) | LMNAHPGDHTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108140448-B | Flexible crosslinked cable insulation and method for manufacturing same | 陶氏环球技术有限责任公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-108350121-B | Procatalyst and polymerization process using the same | 陶氏环球技术有限责任公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-108137855-B | Flexible crosslinked cable insulation and method of making same | 陶氏环球技术有限责任公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3356431-B1 | PROCATALYST AND POLYMERIZATION PROCESS USING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | LMNA 2085/4885HPGD 589/4885HTT 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.